Recent Updates
Recently added Catalysts
PHAR Positive Sentiment

Pharming Group to participate in September investor conferences

Wednesday, September 9, 2026 BiopharmaWatch Research 2 min read
Add on Google
Key Takeaway: Pharming Group N.V. announced its participation in two investor conferences in September 2026. CEO Fabrice Chouraqui will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, followed by participation in the Morgan Stanley 24th Annual Global Healthcare Conference on September 15. The company encourages scheduling one-on-one meetings with its management team.
Price reaction · baseline $11.5 (2026-09-08 close) · hit pre-market · 1 other PHAR headline(s) in the window, move may be shared
day 0 close · peak
-4.6%

Market Sentiment Analysis

POSITIVE FACTORS

  • Pharming is actively engaging with investors at major conferences.
  • The participation in well-known events indicates strong market presence.
  • Management's involvement showcases commitment to transparency and communication.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+15%
120-day peak, hindsight
Typical move
10.1%
average across 4 past catalysts
Lead asset
rhC1INH
Phase 3 · Hereditary Angioedema

Full Press Release Details

Leiden, the Netherlands, September 9, 2026: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) today announced that its management will participate in the following investor conferences in the month of September:
• H.C. Wainwright 28th Annual Global Investment Conference, New York, September 14, 2026 Fabrice Chouraqui, Chief Executive Officer, will present on Monday, September 14 at 09:30 EDT/15:30 CEST. A live webcast and replay of the presentation will be made available in the “Events and presentations” and “Our news” sections of Pharming’s website.
• Morgan Stanley 24th Annual Global Healthcare Conference, New York, September 15, 2026
For more information about these conferences, or to schedule a one-on-one meeting with Pharming’s management team, please contact Pharming’s Investor Relations team at investor@pharming.com or your H.C. Wainwright or Morgan Stanley representative.
About Pharming Group N.V. Pharming Group N.V. (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We develop and commercialize a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with U.S. and European operations.
For more information, visit www.pharming.com and find us on LinkedIn.
For further public information, contact: Pharming Michael Levitan, VP Investor Relations & Capital Markets T: +1 (908) 705 1696 E: investor@pharming.com
Saskia Mehring, Head of Corporate Communications T: +31 6 28 32 60 41 E: media.relations@pharming.com

Media Relations Julia Deutsch (Lyra Strategic Advisory on behalf of Pharming) E: JDeutsch@lyraadvisory.com

Frequently Asked Questions

When will Pharming present at the H.C. Wainwright conference?

Pharming will present on September 14, 2026, at 09:30 EDT.

Which conferences is Pharming participating in September?

Pharming is participating in the H.C. Wainwright and Morgan Stanley conferences.

Who is the CEO of Pharming Group?

Fabrice Chouraqui is the CEO of Pharming Group.

How can investors schedule meetings with Pharming's management?

Investors can contact Pharming's Investor Relations team to schedule meetings.

ShareAdd on Google
Tags: PHAR Pharming investor conferences biopharmaceuticals H.C. Wainwright Morgan Stanley
Last updated: Sep 9, 2026

Biotech snapshot

Lead asset
rhC1INHPhase 3
Hereditary Angioedema →

Catalyst track record

+15%
best trade around PHAR's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PHAR.

See every catalyst's timing & PoA →